Update on IL-17 Inhibitors for Psoriasis

Purpose of Review: We aim to qualify and summarize the major advances afforded by the development of IL-17 inhibitors in the treatment of psoriasis. Recent Findings: Three IL-17 inhibitors are now FDA approved for the treatment of chronic plaque psoriasis, based on robust data supporting the efficacy and safety of secukinumab, ixekizumab, and brodalumab. Summary: This new class of biologics enables an unprecedented level of clearance and has changed the framework and expectations for treatment choices. We can now offer better results to our patients, even those with recalcitrant or difficult-to-treat disease. © 2017, Springer Science+Business Media New York.